Wake Forest Alzheimer's Disease Core Center

总体-项目摘要 本申请提出了一个新的阿尔茨海默病核心中心（ADCC）在维克森林学校的 医学（WFSOM）为病理生理学研究提供全面的基础设施， 预防和治疗AD。我们的中心将提供创新的资源，以审查的贡献 从正常衰老到MCI，然后到AD的早期阶段转换， 其他痴呆症，通过跨越翻译谱的协调研究。维克森林是 独特的装备，以迅速发展一个高影响力的ADCC，因为它有：1）深，跨学科 衰老研究的基础; 2）代谢和血管因素及其 与认知老化和痴呆症的关系; 3）与种族多样性社区的紧密联系， 痴呆症和代谢/血管疾病的患病率;以及4）特殊的机构支持。的 我们的主题的基本原理是基于研究表明，代谢和血管疾病是高度 导致从正常衰老向MCI、AD和其他疾病转变的流行的、可改变的因素 痴呆症为了促进以这些因素为重点的创新转化研究，ADCC将招募一名 来自现有15年代谢/血管风险研究的观察性多种族队列，以及杠杆 他们通过增加关键终点来描述AD和其他痴呆症的广泛数据。临床核心 将招募一个单独的富含代谢/血管风险的队列，沿着AD受试者。的 ADCC将重点关注非洲裔美国人（AA）和其他服务不足的群体，他们有两倍的可能性 发展为AD，并且糖尿病和血管疾病的发病率很高。将提供专门资源 向ADCC研究人员提供，包括用于转化研究的非人灵长类动物（NHP）模型。存储库 人类和NHP生物标本、遗传/表观遗传数据和广泛的临床数据将可用于 NACC，NCRAD和其他调查人员。ADCC还将作为广泛的资源， 反倾销举措。我们的具体目标是：1）建立一个全面的综合研究基础设施 专注于从正常衰老到MCI，AD和其他痴呆症的阶段转变，并提供特殊的 加速代谢和血管因素研究的资源; 2）优化AA的参与 成年人更好地了解其AD和痴呆症风险增加的原因; 3）扩大 与国家ADCC网络和NACC和NCRAD等主要附属机构的关系; 4）提供 对新的研究者进行转化研究培训，并对AD和痴呆症进行教育， 专业人员、患者和家属以及社区。代谢和血管风险的患病率 因素，它们对AD表达的重要性，维克森林科学界在这些方面的优势， 研究领域，以及我们杰出的机构承诺是NIH资金将 成功地利用这些资源建立了一个ADCC，将为实地做出重大贡献。

Overall – Project Summary This application proposes a new Alzheimer's Disease Core Center (ADCC) at Wake Forest School of Medicine (WFSOM) to provide a comprehensive infrastructure for research on the pathophysiology, prevention, and treatment of AD. Our Center will provide innovative resources to examine the contributions of metabolic and vascular factors to early phase transitions from normal aging to MCI and then to AD and other dementias, through coordinated research spanning the translational spectrum. Wake Forest is uniquely equipped to rapidly develop a high-impact ADCC because it has: 1) a deep, interdisciplinary foundation in aging research; 2) specialized expertise in metabolic and vascular factors and their relationship to cognitive aging and dementia; 3) strong ties to an ethnically diverse community with high prevalence of dementia and metabolic/vascular disorders; and 4) exceptional institutional support. The rationale for our theme is based on research showing that metabolic and vascular disorders are highly prevalent, modifiable factors that contribute to the transitions from normal aging to MCI, AD, and other dementias. To promote innovative translational research focused on these factors, the ADCC will enroll an observational multi-ethnic cohort from an existing 15-year study of metabolic/vascular risk, and leverage their extensive data by adding key endpoints to characterize AD and other dementias. The Clinical Core will enroll a separate cohort enriched for metabolic/vascular risk, along with participants with AD. The ADCC will focus on African-American (AA) and other underserved groups who are twice as likely to develop AD, and have high rates of diabetes and vascular disease. Specialized resources will be available to ADCC investigators, including non-human primate (NHP) models for translational research. A repository of human and NHP biospecimens, genetic/epigenetic data, and extensive clinical data will be available to NACC, NCRAD, and other investigators. The ADCC will also serve as a resource for a broad spectrum of AD initiatives. Our Specific Aims are to: 1) Establish a comprehensive integrated research infrastructure focused on phase transitions from normal aging to MCI, AD, and other dementias, and provide special resources to accelerate research on metabolic and vascular factors; 2) Optimize the participation of AA adults to better understand the causes underlying their increased risk of AD and dementia; 3) Expand relationships with the national ADCC network and key affiliates such as NACC and NCRAD; 4) Provide training in translational research to new investigators, and education regarding AD and dementia to professionals, patients and families, and the community. The prevalence of metabolic and vascular risk factors, their importance to AD expression, the strengths of the Wake Forest scientific community in these research areas, and our outstanding institutional commitment are indicators that NIH funding will be successfully leveraged to establish an ADCC that will make high-impact contributions to the field.